COMPARISON OF EFFICACY AND TOLERANCE OF THE INTRAPERITONEAL CELL-BASED AND IL-2 IMMUNOTHERAPY OF PATIENTS WITH CHEMOTHERAPY-RESISTANT GASTRIC CANCER AND MALIGNANT ASCITES

K. S Titov; L. V Demidov; I. Zh Shubina; M. V Kiselevsky

doi:10.17816/onco40053

Russian Journal of Oncology ›› 2014, Vol. 19 ›› Issue (3) : 24 -28. DOI: 10.17816/onco40053

Articles

research-article

COMPARISON OF EFFICACY AND TOLERANCE OF THE INTRAPERITONEAL CELL-BASED AND IL-2 IMMUNOTHERAPY OF PATIENTS WITH CHEMOTHERAPY-RESISTANT GASTRIC CANCER AND MALIGNANT ASCITES

Author information +

History +

PDF

Abstract

Most often gastric cancer is accompanied with abdominal carcinomatosis tumor (metastases) ascites (25 %), which is a life-threatening complications of tumor process, often recurring after systemic drug therapy which not always leads to a longer remission, but is also accompanied by severe side effects. Intraperitoneal immunotherapy of metastatic ascites interleukin-2 (IL-2) in combination with allogeneic (donor) lymphokine - activated killer (LAK) and IL-2 monotherapy is highly effective and well tolerated in patients with gastric cancer. Objective effect of the treatment was 50.0 % and 42.8 %, respectively. Proposed form of immunotherapy can be considered as one of the stages combined drug treatment, has good tolerance and improves their quality of life.

Keywords

gastric cancer / peritoneal carcinomatosis / ascites tumor / interleukin-2 / LAK cells / intraperitoneal immunotherapy

Cite this article

Download citation ▾

K. S Titov, L. V Demidov, I. Zh Shubina, M. V Kiselevsky. COMPARISON OF EFFICACY AND TOLERANCE OF THE INTRAPERITONEAL CELL-BASED AND IL-2 IMMUNOTHERAPY OF PATIENTS WITH CHEMOTHERAPY-RESISTANT GASTRIC CANCER AND MALIGNANT ASCITES. Russian Journal of Oncology, 2014, 19(3): 24-28 DOI:10.17816/onco40053

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Базин И.С. Лекарственная терапия рака желудка и рака толстой кишки: Дисс. д-ра мед. наук. М.; 2009.

[2]	Гарин А.М., Базин И.С. Рак желудка. В кн.: Десять наиболее распространенных злокачественных опухолей. М.; 2010.

[3]	Сельчук В.Ю., Бычков М.Б., Киселевский М.В., ред. Опухолевые серозиты. М.: Практическая медицина; 2011.

[4]	Ajani J.A., Fodor M., Van Cutsem E. et al. Multinational randomized phase II trial of docetaxel and cisplatin with or without 5-fluorouracil in patients with advanced gastric GE function adenocarcinoma. In: Proceedings ASCO. 2000: abstr. 957.

[5]	Feedman R.S., Kudelka A.P., Kavanagh J.J. Clinical and biological effects of intraperitoneal injections of recombinant interferon-γ and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin. Cancer Res. 2000; 6: 226-35.

[6]	Beecham J.B., Kucera P., Helmkamp B.F., Bonfiglio T.A. Peritoneal angiogenesis in patients with ascites. Gynecol. Oncol. 1983; 15: 142.

[7]	Fastaia J., Dumont A.E. Pathogenesis of ascites in mice with peritoneal carcinomatosis. J. Natl. Cancer Inst. 1976; 56 (3): 547-50.

[8]	Garrison R.N., Vaclin L.D., Galloway R.H., Heuser L.S. Malignant ascites. Clinical and experimental observations. Ann. Surg. 1986; 203: 644-65.

[9]	Hamaguchi T., Ohtsu A., Hyodo I. et al. A phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine- resistant advanced gastric cancer. The Japan Clinical Oncology Group Trial. In: Proceedings ASCO. 2004: abstr. 4071.

[10]	Moiseyenco V., Van Cutsem E., Tuljandin S. et al. Docetaxelcisplatin-fluorouracil versus cisplatin-5 fluorouracil as first line therapy for gastric: the interim analysis results on efficacy and safety in a multicenter randomized phase III study. In: Proceedings ASCO. 2002: abstr. 187.

[11]	Sato A., Kurihara M., Koizumi W. et al. A phase II study of UFT plus cisplatin therapy in patients with advanced gastric cancer. In: Proceedings ASCO. 2000: abstr. 1087.

[12]	Shirao K., Muro K., Jamada Y. et al. A phase I/II study of irinotecan combined with mitomycin C in patients with advanced gastric cancer. In: Proceedings of the 4th International conference biol. prev. treatment gastrointestinl malign. cologne. 2000: abstr. 7.

[13]	Давыдов М.И., Летягин В.П., Кузнецов В.В. Рак яичников. В кн.: Опухоли женской репродуктивной системы. М.: Радуга; 2007: 273-82.

[14]	Pujade-Lauraine E., Guastella J.P., Colombo N. et al. Intraperitoneal ecombinant interferon-y in ovarian cancer patients with residual disease at second-look laparotomy. J. Clin. Oncol. 1996; 14: 343-50.

[15]	Титов К.С., Демидов Л.В., Киселевский М.В., Шубина И.Ж. и др. Внутриплевральная иммунотерапия интерлейкином-2 у больных с метастатическим плевритом. Российский онкологический журнал. 2010; 4: 20-4.

[16]	Liu X., Li D., Zhang C., Ba D. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogenic LAK cells combined with rIL-2. Med. Sci. J. 1993; 8: 186-9.